SBRT for Prostate Cancer

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Hoag Memorial Hospital Presbyterian

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to learn the long term efficacy and side effects associated with utilizing Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System. SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer. Traditional External beam radiation therapy (EBRT) for prostate carcinoma is typically done over the course of approximately 42-45 daily treatments SBRT is a way to condense this treatment into a course of 5 treatments, delivering more dose per day.

Eligibility Criteria

This trial is for men over 18 with early to moderately advanced prostate cancer (stage T1-3) who haven't had previous treatments like surgery, cryosurgery, or radiation. They must be able to consent and fill out a quality of life questionnaire. Men with distant metastases, lymph node involvement, severe bowel disease, or prior chemotherapy are excluded.

Inclusion Criteria

My cancer is in an early to mid-stage, not the most advanced.

I have had a physical exam that included a prostate check.

I am a man aged 18 or older.

+4 more

Exclusion Criteria

My cancer has spread to distant parts of my body.

Performance Status will not be considered

There are no restrictions based on your life expectancy.

+5 more

Participant Groups

The study tests the effectiveness and side effects of Stereotactic Body Radiation Therapy (SBRT) using Elekta Versa or Agility Systems in treating prostate cancer. SBRT is an advanced technique delivering targeted radiation in fewer sessions compared to traditional therapy—5 versus 42-45 treatments.

2Treatment groups

Experimental Treatment

Active Control

Group I: Agility SystemsExperimental Treatment1 Intervention

This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.

Group II: Elekta Versa HDActive Control1 Intervention

This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.